Clinical Trials Logo

Clinical Trial Summary

A multicenter, randomized, double-blind, placebo-controlled, group-comparison study to investigate the safety and efficacy of OPC-262 in patients with type 2 diabetes


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT00857558
Study type Interventional
Source Kyowa Hakko Kirin Co., Ltd
Contact
Status Completed
Phase Phase 2
Start date January 2009
Completion date May 2010

See also
  Status Clinical Trial Phase
Completed NCT01805414 - Breakfast Nutrition and Inpatient Glycemia N/A
Completed NCT01427660 - iDecide.Decido: Diabetes Medication Decision Support Study N/A
Completed NCT02648685 - The Study to Investigate the Contribution of Basal and Postprandial Glucose to Overall Hyperglycemia in T2DM
Completed NCT00141232 - Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes Phase 4
Completed NCT03397225 - A Lifestyle Intervention for Type 2 Diabetes Patients in Kuwait and Its Impact on Glycaemic Control N/A
Completed NCT01837680 - Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy N/A
Completed NCT01336738 - Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus Phase 2
Completed NCT00308737 - Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes Phase 3
Completed NCT00246987 - A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control Phase 3
Completed NCT01193179 - A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes Phase 3
Terminated NCT01350102 - The Relationship of Hemoglobin A1c and Diabetic Wound Healing Phase 4
Completed NCT01624116 - Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetes N/A
Completed NCT01634282 - Along-term Study of OPC-262 in Patients With Type 2 Diabetes Phase 3
Withdrawn NCT02222623 - The Inova Type 2 Diabetes Mellitus Study N/A
Recruiting NCT06340854 - A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes Phase 3